<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02074631</url>
  </required_header>
  <id_info>
    <org_study_id>2013LS023</org_study_id>
    <nct_id>NCT02074631</nct_id>
  </id_info>
  <brief_title>Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation</brief_title>
  <official_title>Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open-label, randomized, controlled clinical study of pediatric subjects
      treated with pamidronate with calcium and vitamin D versus calcium and vitamin D alone
      following hematopoietic cell transplantation (HCT). The purpose of this study is to test the
      hypothesis that subjects receiving pamidronate with calcium and vitamin D will have higher
      lumbar spine bone mineral content (LBMC) measured by dual-energy X-ray tomography (DXA) at 1
      year post-HCT than subjects receiving calcium and vitamin D alone (Control Group).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lumbar spine bone mineral content</measure>
    <time_frame>1 year after HCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total body bone mineral content (TBMC; excluding head; adjusted for height, age, sex, Tanner stage, and race)</measure>
    <time_frame>1 year after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bone mineral density (BMD), cortical BMD, trabecular BMD, and estimated bone strength measured by pQCT</measure>
    <time_frame>1 year after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine levels (interleukin IL-6, IL-7, and TNF-α)</measure>
    <time_frame>7 days, 14 days, 21 days, 100 days after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receptor activator of the nuclear factor-κB ligand [RANKL], osteoprotegerin [OPG], RANKL/OPG ratio</measure>
    <time_frame>7 days, 14 days, 21 days, and 100 days after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of bone resorption (carboxy-terminal collagen crosslinks [CTX] and deoxypyridinoline [DPD])</measure>
    <time_frame>7, 14, 21, 100, 180, 360 days after HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of bone formation (procollagen type 1 N-terminal propeptide [P1NP] and osteocalcin [OCN])</measure>
    <time_frame>7, 14, 21, 100, 180, 360 days after HCT</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive a standard recommended dose of calcium and vitamin D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pamidronate Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to pamidronate treatment will receive infusions approximately 100, 180, and 270 days after HCT along with calcium and vitamin D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pamidronate</intervention_name>
    <description>Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.</description>
    <arm_group_label>Pamidronate Group</arm_group_label>
    <other_name>Aredia</other_name>
    <other_name>Bonapam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium and vitamin D</intervention_name>
    <description>All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Pamidronate Group</arm_group_label>
    <other_name>Cholecalciferol</other_name>
    <other_name>Ergocalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allogeneic hematopoietic cell transplant for hematologic malignancy (i.e. leukemia,
             lymphoma including ALL, AML, CML, NHL, HL) in complete remission; myelodysplastic
             syndrome (active dysplasia and/or blasts are permitted, but must not have active
             leukemia) or idiopathic severe aplastic anemia (SAA)

          -  Non-malignant diseases including idiopathic severe aplastic anemia (SAA) and other
             bone marrow failure disorders, hemoglobinopathies, adrenoleukodystrophy, immune
             deficiencies/dysregulation disorders who will be receiving myeloablative or reduced
             toxicity preparative regimens that meet the following criteria:

               -  Regimens include those that are TBI based if the TBI dose is &gt; 500cGy single dose
                  or &gt; 800cGy fractionated, or doses &lt;500 cGy if combined with busulfan or
                  treosulfan. These also include chemotherapy only based regimens that contain
                  myeloablative doses of busulfan (&gt;8mg/kg) or treosulfan without TBI.

               -  Patients with severe aplastic anemia are eligible regardless of conditioning
                  regimen

          -  Myeloablative preparative regimen (for SAA any conditioning therapy allowed)

          -  Male or female ≥1 but ≤ 20 years of age at time of study enrollment

          -  Patient or parent(s)/legal guardian(s) is able and willing to provide informed
             consent. Assent will be obtained per local institutional policy. Subjects who turn 18
             during the course of the study will be consented at that time of their next visit by a
             member of the research staff.

        Exclusion Criteria:

          -  History of a primary bone malignancy involving the lumbar spine

          -  Prior and/or planned concomitant medical therapy during the study period (through Day
             360 post-HCT) with other bisphosphonates, Denosumab, or Teriparatide

          -  Pregnancy or breastfeeding - menstruating females must have a negative pregnancy test
             prior to study enrollment and agree to repeat pregnancy testing and contraception use
             per protocol as pamidronate is Pregnancy Category D - positive evidence of human fetal
             risk based on adverse reaction data

          -  Renal insufficiency, defined as creatinine level greater than the upper limit of
             normal for age

          -  Hereditary metabolic bone disease or skeletal dysplasia (e.g., osteopetrosis or OI) or
             primary hyperparathyroidism

          -  Other indications for HCT, including Fanconi anemia, other form of inherited bone
             marrow failure diseases, metabolic disorder, hemoglobinopathy, or immune deficiency

          -  Clinically significant fractures as defined by ISCD (a long bone fracture of the lower
             extremities, vertebral compression fracture, or two or more long bone fractures of the
             upper extremities) (88,89) indicated by a cast or a spine x-ray within the last 2
             weeks

          -  Known or suspected allergy to pamidronate or related products

          -  Planned administration of an investigational study drug or agent that either can
             interact with pamidronate or have an independent effect on bone mineral density within
             the 4 weeks prior to randomization (Day 90) or planned use during study participation
             (Day 90 through Day 360)

          -  Impending invasive dental procedure that would be expected to occur during study
             participation (through Day 360)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriakie Sarafoglou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Nelson, RN</last_name>
    <phone>612-273-2925</phone>
    <email>knelso62@fairview.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyriakie Sarafoglou, MD</last_name>
    <phone>(612) 624-0123</phone>
    <email>saraf010@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Minnesota Amplatz Children's Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Nelson, RN</last_name>
      <phone>612-273-2925</phone>
      <email>knelso62@fairview.org</email>
    </contact>
    <investigator>
      <last_name>Kyriakie Sarafoglou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Baker, M.D.</last_name>
      <phone>206-667-5594</phone>
      <email>ksbaker@fhcrc.org</email>
    </contact>
    <investigator>
      <last_name>Scott Baker, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Petryk A, Bergemann TL, Polga KM, Ulrich KJ, Raatz SK, Brown DM, Robison LL, Baker KS. Prospective study of changes in bone mineral density and turnover in children after hematopoietic cell transplantation. J Clin Endocrinol Metab. 2006 Mar;91(3):899-905. Epub 2005 Dec 13.</citation>
    <PMID>16352681</PMID>
  </reference>
  <reference>
    <citation>Bhatia S, Ramsay NK, Weisdorf D, Griffiths H, Robison LL. Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies. Bone Marrow Transplant. 1998 Jul;22(1):87-90.</citation>
    <PMID>9678801</PMID>
  </reference>
  <reference>
    <citation>Nysom K, Holm K, Michaelsen KF, Hertz H, Jacobsen N, Müller J, Mølgaard C. Bone mass after allogeneic BMT for childhood leukaemia or lymphoma. Bone Marrow Transplant. 2000 Jan;25(2):191-6.</citation>
    <PMID>10673679</PMID>
  </reference>
  <reference>
    <citation>Kaste SC, Shidler TJ, Tong X, Srivastava DK, Rochester R, Hudson MM, Shearer PD, Hale GA. Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004 Feb;33(4):435-41.</citation>
    <PMID>14716354</PMID>
  </reference>
  <reference>
    <citation>Perkins JL, Kunin-Batson AS, Youngren NM, Ness KK, Ulrich KJ, Hansen MJ, Petryk A, Steinberger J, Anderson FS, Baker KS. Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer. 2007 Dec;49(7):958-63.</citation>
    <PMID>17474113</PMID>
  </reference>
  <reference>
    <citation>Daniels MW, Wilson DM, Paguntalan HG, Hoffman AR, Bachrach LK. Bone mineral density in pediatric transplant recipients. Transplantation. 2003 Aug 27;76(4):673-8.</citation>
    <PMID>12973107</PMID>
  </reference>
  <reference>
    <citation>Mostoufi-Moab S, Ginsberg JP, Bunin N, Zemel B, Shults J, Leonard MB. Bone density and structure in long-term survivors of pediatric allogeneic hematopoietic stem cell transplantation. J Bone Miner Res. 2012 Apr;27(4):760-9. doi: 10.1002/jbmr.1499.</citation>
    <PMID>22189761</PMID>
  </reference>
  <reference>
    <citation>Jackowski SA, Kontulainen SA, Cooper DM, Lanovaz JL, Baxter-Jones AD. The timing of BMD and geometric adaptation at the proximal femur from childhood to early adulthood in males and females: a longitudinal study. J Bone Miner Res. 2011 Nov;26(11):2753-61. doi: 10.1002/jbmr.468.</citation>
    <PMID>21773991</PMID>
  </reference>
  <reference>
    <citation>Kaste SC, Rai SN, Fleming K, McCammon EA, Tylavsky FA, Danish RK, Rose SR, Sitter CD, Pui CH, Hudson MM. Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2006 Jan;46(1):77-87.</citation>
    <PMID>16106430</PMID>
  </reference>
  <reference>
    <citation>Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. 1991 Jun 1;114(11):919-23.</citation>
    <PMID>2024857</PMID>
  </reference>
  <reference>
    <citation>Baxter-Jones AD, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA. Bone mineral accrual from 8 to 30 years of age: an estimation of peak bone mass. J Bone Miner Res. 2011 Aug;26(8):1729-39. doi: 10.1002/jbmr.412.</citation>
    <PMID>21520276</PMID>
  </reference>
  <reference>
    <citation>Polgreen LE, Rudser K, Deyo M, Smith A, Baker KS, Petryk A. Changes in biomarkers of bone resorption over the first six months after pediatric hematopoietic cell transplantation. Pediatr Transplant. 2012 Dec;16(8):852-7. doi: 10.1111/j.1399-3046.2012.01780.x. Epub 2012 Aug 20.</citation>
    <PMID>22905997</PMID>
  </reference>
  <reference>
    <citation>Grigg AP, Shuttleworth P, Reynolds J, Schwarer AP, Szer J, Bradstock K, Hui C, Herrmann R, Ebeling PR. Pamidronate reduces bone loss after allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2006 Oct;91(10):3835-43. Epub 2006 Jul 11.</citation>
    <PMID>16835281</PMID>
  </reference>
  <reference>
    <citation>Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Välimäki MJ. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab. 2005 Jul;90(7):3877-85. Epub 2005 Mar 29.</citation>
    <PMID>15797959</PMID>
  </reference>
  <reference>
    <citation>Glorieux FH. Treatment of osteogenesis imperfecta: who, why, what? Horm Res. 2007;68 Suppl 5:8-11. doi: 10.1159/000110463. Epub 2007 Dec 10. Review.</citation>
    <PMID>18174695</PMID>
  </reference>
  <reference>
    <citation>Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone. 2007 Mar;40(3):638-44. Epub 2006 Nov 28.</citation>
    <PMID>17127117</PMID>
  </reference>
  <reference>
    <citation>Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol. 1987;16(5):360-3.</citation>
    <PMID>3629280</PMID>
  </reference>
  <reference>
    <citation>Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004 Apr 24;363(9418):1377-85. Review.</citation>
    <PMID>15110498</PMID>
  </reference>
  <reference>
    <citation>Speiser PW, Clarson CL, Eugster EA, Kemp SF, Radovick S, Rogol AD, Wilson TA; LWPES Pharmacy and Therapeutic Committee. Bisphosphonate treatment of pediatric bone disease. Pediatr Endocrinol Rev. 2005 Dec;3(2):87-96. Review.</citation>
    <PMID>16361982</PMID>
  </reference>
  <reference>
    <citation>Castillo H, Samson-Fang L; American Academy for Cerebral Palsy and Developmental Medicine Treatment Outcomes Committee Review Panel. Effects of bisphosphonates in children with osteogenesis imperfecta: an AACPDM systematic review. Dev Med Child Neurol. 2009 Jan;51(1):17-29. doi: 10.1111/j.1469-8749.2008.03222.x. Review.</citation>
    <PMID>19087101</PMID>
  </reference>
  <reference>
    <citation>DiMeglio LA, Ford L, McClintock C, Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone. 2004 Nov;35(5):1038-45.</citation>
    <PMID>15542028</PMID>
  </reference>
  <reference>
    <citation>Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998 Oct 1;339(14):947-52.</citation>
    <PMID>9753709</PMID>
  </reference>
  <reference>
    <citation>Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr. 2002 Nov;141(5):644-51.</citation>
    <PMID>12410192</PMID>
  </reference>
  <reference>
    <citation>Plotkin H, Coughlin S, Kreikemeier R, Heldt K, Bruzoni M, Lerner G. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: a pilot study. Dev Med Child Neurol. 2006 Sep;48(9):709-12. Erratum in: Dev Med Child Neurol. 2006 Dec;48(12):1024.</citation>
    <PMID>16904014</PMID>
  </reference>
  <reference>
    <citation>Grissom LE, Kecskemethy HH, Bachrach SJ, McKay C, Harcke HT. Bone densitometry in pediatric patients treated with pamidronate. Pediatr Radiol. 2005 May;35(5):511-7. Epub 2005 Jan 18.</citation>
    <PMID>15655696</PMID>
  </reference>
  <reference>
    <citation>Gandrud LM, Cheung JC, Daniels MW, Bachrach LK. Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol Metab. 2003 Jul-Aug;16(6):887-92.</citation>
    <PMID>12948302</PMID>
  </reference>
  <reference>
    <citation>Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore). 1997 Jul;76(4):266-83. Review.</citation>
    <PMID>9279333</PMID>
  </reference>
  <reference>
    <citation>Przkora R, Herndon DN, Sherrard DJ, Chinkes DL, Klein GL. Pamidronate preserves bone mass for at least 2 years following acute administration for pediatric burn injury. Bone. 2007 Aug;41(2):297-302. Epub 2007 May 8.</citation>
    <PMID>17561466</PMID>
  </reference>
  <reference>
    <citation>Carpenter PA, Hoffmeister P, Chesnut CH 3rd, Storer B, Charuhas PM, Woolfrey AE, Sanders JE. Bisphosphonate therapy for reduced bone mineral density in children with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007 Jun;13(6):683-90. Epub 2007 Apr 6.</citation>
    <PMID>17531778</PMID>
  </reference>
  <reference>
    <citation>Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003 Jul 31;349(5):457-63.</citation>
    <PMID>12890844</PMID>
  </reference>
  <reference>
    <citation>Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab. 2003 Mar;88(3):986-92.</citation>
    <PMID>12629073</PMID>
  </reference>
  <reference>
    <citation>Aström E, Söderhäll S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002 May;86(5):356-64.</citation>
    <PMID>11970931</PMID>
  </reference>
  <reference>
    <citation>Steelman J, Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr. 2003 Apr;142(4):417-23.</citation>
    <PMID>12712060</PMID>
  </reference>
  <reference>
    <citation>Ward LM, Denker AE, Porras A, Shugarts S, Kline W, Travers R, Mao C, Rauch F, Maes A, Larson P, Deutsch P, Glorieux FH. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab. 2005 Jul;90(7):4051-6. Epub 2005 Apr 12.</citation>
    <PMID>15827104</PMID>
  </reference>
  <reference>
    <citation>Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab. 2002 Feb;15(2):163-74.</citation>
    <PMID>11874181</PMID>
  </reference>
  <reference>
    <citation>Janssen van Doorn K, Neyns B, Van der Niepen P, Verbeelen D. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron. 2001 Dec;89(4):467-8.</citation>
    <PMID>11721169</PMID>
  </reference>
  <reference>
    <citation>Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol. 1996 Mar;45(3):175-9.</citation>
    <PMID>8706358</PMID>
  </reference>
  <reference>
    <citation>Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996 Feb;18(2):75-85. Review.</citation>
    <PMID>8833200</PMID>
  </reference>
  <reference>
    <citation>Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med. 2007 Mar 8;356(10):1075-6.</citation>
    <PMID>17347467</PMID>
  </reference>
  <reference>
    <citation>Ward KA, Adams JE, Freemont TJ, Mughal MZ. Can bisphosphonate treatment be stopped in a growing child with skeletal fragility? Osteoporos Int. 2007 Aug;18(8):1137-40. Epub 2007 Feb 6.</citation>
    <PMID>17279467</PMID>
  </reference>
  <reference>
    <citation>Rauch F, Cornibert S, Cheung M, Glorieux FH. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone. 2007 Apr;40(4):821-7. Epub 2007 Jan 12.</citation>
    <PMID>17223617</PMID>
  </reference>
  <reference>
    <citation>Whyte MP, McAlister WH, Novack DV, Clements KL, Schoenecker PL, Wenkert D. Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res. 2008 Oct;23(10):1698-707. doi: 10.1359/jbmr.080511.</citation>
    <PMID>18505375</PMID>
  </reference>
  <reference>
    <citation>Janz KF, Letuchy EM, Eichenberger Gilmore JM, Burns TL, Torner JC, Willing MC, Levy SM. Early physical activity provides sustained bone health benefits later in childhood. Med Sci Sports Exerc. 2010 Jun;42(6):1072-8. doi: 10.1249/MSS.0b013e3181c619b2.</citation>
    <PMID>19997029</PMID>
  </reference>
  <reference>
    <citation>Meyer U, Romann M, Zahner L, Schindler C, Puder JJ, Kraenzlin M, Rizzoli R, Kriemler S. Effect of a general school-based physical activity intervention on bone mineral content and density: a cluster-randomized controlled trial. Bone. 2011 Apr 1;48(4):792-7. doi: 10.1016/j.bone.2010.11.018. Epub 2010 Dec 15.</citation>
    <PMID>21167330</PMID>
  </reference>
  <reference>
    <citation>Buison AM, Kawchak DA, Schall JI, Ohene-Frempong K, Stallings VA, Leonard MB, Zemel BS. Bone area and bone mineral content deficits in children with sickle cell disease. Pediatrics. 2005 Oct;116(4):943-9.</citation>
    <PMID>16199706</PMID>
  </reference>
  <reference>
    <citation>Burnham JM, Shults J, Semeao E, Foster B, Zemel BS, Stallings VA, Leonard MB. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res. 2004 Dec;19(12):1961-8. Epub 2004 Sep 20.</citation>
    <PMID>15537438</PMID>
  </reference>
  <reference>
    <citation>Horlick M, Wang J, Pierson RN Jr, Thornton JC. Prediction models for evaluation of total-body bone mass with dual-energy X-ray absorptiometry among children and adolescents. Pediatrics. 2004 Sep;114(3):e337-45.</citation>
    <PMID>15342895</PMID>
  </reference>
  <reference>
    <citation>Petryk A, Polgreen LE, Zhang L, Hodges JS, Dengel DR, Hoffmeister PA, Steinberger J, Baker KS. Bone mineral deficits in recipients of hematopoietic cell transplantation: the impact of young age at transplant. Bone Marrow Transplant. 2014 Feb;49(2):258-63. doi: 10.1038/bmt.2013.156. Epub 2013 Oct 14.</citation>
    <PMID>24121211</PMID>
  </reference>
  <reference>
    <citation>Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969 Jun;44(235):291-303.</citation>
    <PMID>5785179</PMID>
  </reference>
  <reference>
    <citation>Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970 Feb;45(239):13-23.</citation>
    <PMID>5440182</PMID>
  </reference>
  <reference>
    <citation>Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6. Erratum in: J Clin Endocrinol Metab. 2011 Dec;96(12):3908.</citation>
    <PMID>21646368</PMID>
  </reference>
  <reference>
    <citation>Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011 Jan;96(1):53-8. doi: 10.1210/jc.2010-2704. Epub 2010 Nov 29.</citation>
    <PMID>21118827</PMID>
  </reference>
  <reference>
    <citation>Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M; Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics. 2008 Aug;122(2):398-417. doi: 10.1542/peds.2007-1894. Review.</citation>
    <PMID>18676559</PMID>
  </reference>
  <reference>
    <citation>Gordon CM, Williams AL, Feldman HA, May J, Sinclair L, Vasquez A, Cox JE. Treatment of hypovitaminosis D in infants and toddlers. J Clin Endocrinol Metab. 2008 Jul;93(7):2716-21. doi: 10.1210/jc.2007-2790. Epub 2008 Apr 15.</citation>
    <PMID>18413426</PMID>
  </reference>
  <results_reference>
    <citation>Tauchmanovà L, Colao A, Lombardi G, Rotoli B, Selleri C. Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab. 2007 Dec;92(12):4536-45. Epub 2007 Oct 2. Review.</citation>
    <PMID>17911175</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2014</study_first_submitted>
  <study_first_submitted_qc>February 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2014</study_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone mineral content</keyword>
  <keyword>bone mineral density</keyword>
  <keyword>bone formation</keyword>
  <keyword>bone resorption</keyword>
  <keyword>pamidronate</keyword>
  <keyword>children</keyword>
  <keyword>DXA</keyword>
  <keyword>bone marrow transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

